Afatinib Dimaleate Intermedia CAS 314771-88-5 Puritas >99.0% (HPLC) Factory
Ruifu Chemical Supple intermedia de Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
acetaldehyda Diethyl acetalis CAS 3616-56-6
trans-4-dimethylaminocrotonic Acidum hydrochloridum CAS 848133-35-75
Diethylphosphonoaceticum acidum CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4(1H)-one CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl) -7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-AmineCAS 314771-88-5
Nomen chemicum | (S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-Amine |
Synonyma | N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-[(3S)-oxolan-3-yl] oxyquinazolin-4-Amine;7-((S)-Tetrahydrofuran-3-yloxy) -4-(3-Chloro-4-Fluorophenyl)amino-6-Nitroquinazoline;Afatinib immunditia |
CAS Number | 314771-88-5 |
CATTUS Number | RF-PI2027 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C18H14ClFN4O4 |
M. Pondus | 404.78 |
Density | 1.534±0.060 g/cm3 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Yellow ad lux flavo pulveris |
Puritas / Analysis Methodus | >99.0% (HPLC) |
Damnum in Siccatio | <0.50% |
Individual Impurity | <0.50% |
Totalis immunditias | <1.00% |
Metalla gravis | ≤20ppm |
Test Standard | Enterprise Standard |
Consuetudinem | Afatinib Dimaleate (CAS: 850140-73-7) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-Amine (CAS: 314771-88-5) adhibetur in Praeparatio Afatinib Dimaleate (CAS: 850140-73-7).Afatinib est porttitor anti-cancri scopum medicamentum, nova generatio scopo oralis medicamento, primum pharmacum anti-cancri scopum mundi, quod irreversibiliter obligat ad familiam ErbB, et efficacior est et iaculis impedit signum quod incrementum cellulis cancri trigger. reducendo vel differendo cellularum cancri multiplicationem.Afatinib ad genus medicamentorum quae inhibitores tyrosini kinase vocantur.Munus duorum servo propinquorum arcte intercluso operatur, factor incrementi epidermalis receptoris (EGFR) et factor incrementi humani epidermalis receptoris 2 (ER2).Usus primae lineae curationis aegrorum cum cancro metastatico cellae pulmonis non parvae.Afatinib est porttitor anti-cancri scopum medicamentum, nova generatio scopo oralis medicamento, primum pharmacum anti-cancri scopum mundi, quod irreversibiliter obligat ad familiam ErbB, et efficacior est et iaculis impedit signum quod incrementum cellulis cancri trigger. reducendo vel differendo cellularum cancri multiplicationem.